Last reviewed · How we verify
clopidogrel bisulfate + aspirin
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots.
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention of cardiovascular events post-percutaneous coronary intervention, Stroke prevention in patients with recent myocardial infarction or unstable angina.
At a glance
| Generic name | clopidogrel bisulfate + aspirin |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 synthesis. Together, they provide dual antiplatelet therapy with synergistic effects on preventing thrombotic events by targeting different platelet activation mechanisms.
Approved indications
- Acute coronary syndrome
- Secondary prevention of cardiovascular events post-percutaneous coronary intervention
- Stroke prevention in patients with recent myocardial infarction or unstable angina
Common side effects
- Bleeding
- Dyspepsia
- Rash
- Diarrhea
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clopidogrel bisulfate + aspirin CI brief — competitive landscape report
- clopidogrel bisulfate + aspirin updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI